On September 4, 2026, in San Carlos, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotech firm specializing in pioneering polyclonal tumor infiltrating lymphocyte (TIL) treatments for cancer patients, revealed that its senior executives will be speaking at several forthcoming conferences.